article Open AccessTop 1% cited

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

Annals of Oncology · 2004 · Vol. 15(3) · pp. 440–449

E O’Brien✉(Maidstone Hospital)Nely Wigler(Tel Aviv Sourasky Medical Center)Moshe Inbar(Tel Aviv Sourasky Medical Center)R. Rosso(Associazione Italiana Di Oncologia Medica)Eva‐Maria Grischke(Heidelberg University)Armando Santoro(Fondazione Humanitas per la Ricerca)Raphael Catane(Shaare Zedek Medical Center)D G Kieback(Maastricht University)Piotr Tomczak(Hematology\Oncology Clinic)Stephen P. Ackland(Mater Misericordiae Hospital)F. Orlandi(Hospital Dipreca)L. Mellars(Merck (Japan))Leila Alland(Merck (Japan))Craig Tendler(Merck (Japan))

View via DOI Full-text PDF

Chemotherapy-induced cardiotoxicity and mitigation Cancer Treatment and Pharmacology Chemotherapy-related skin toxicityMedicineCardiotoxicityMucositisDoxorubicinMetastatic breast cancerInternal medicineAnthracyclineVomitingNeutropeniaNausea

MeSH terms

AdultAgedAged, 80 and overAntibiotics, AntineoplasticBreast NeoplasmsDoxorubicinFemaleHeart DiseasesHumansLiposomesMiddle AgedPolyethylene GlycolsPrognosisSurvival RateTreatment Outcome

Citations

1,701

FWCI

26.08

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines